(CercleFinance.com) – AB Science shares fell on the stock market this Monday after the decision of the Committee for Medicinal Products for Human Use (CHMP) to postpone the date of the regulatory evaluation of its treatment against amyotrophic lateral sclerosis (ALS).
On the Paris Stock Exchange, the pharmaceutical company’s shares fell more than 12%, marking one of the biggest declines on the market.
AB Science explains that the CHMP, an arm of the European Medicines Agency (EMA), asked it to respond in writing to certain questions that remained unanswered within the framework of the procedure, instead of addressing these questions during an oral presentation.
If AB Science recognizes that this decision is ‘unusual’ at this stage of the procedure, the company says it has accepted it to the extent that it will allow it to provide more detailed answers and to give the CHMP
more time to evaluate their responses.
Initially, the oral presentation was scheduled for January 24, which suggested that the committee’s verdict would likely be delivered sometime in February 2024.
This hearing having now been canceled to be replaced by a written response, the CHMP verdict is now postponed to the second quarter, specifies AB Science in its press release.